eca is a $12.44 billion healthcare
business with more than 12,000 employees. For nearly three decades,
AstraZeneca has offered drug assistance programs side by side with its
medicines, and over the past five years, has provided over $3 billion in
savings to more than 1 million patients throughout the US and Puerto Rico.
AstraZeneca has been named one of the "100 Best Companies for Working
Mothers" by Working Mother magazine and is the only large pharmaceutical
company named to FORTUNE magazine's 2007 list of "100 Best Companies to
Work For." In 2006, for the fifth consecutive year, Science magazine named
AstraZeneca a "Top Employer" on its ranking of the world's most respected
For more information about AstraZeneca, please visit:
The statements herein include forward-looking statements. By their
nature, forward-looking statements and forecasts involve risk and
uncertainty. For a discussion of those risks and uncertainties please see
the company's Annual Report/Form 20-F for 2006.
(1) Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in
schizophrenia and their relevance for psychopharmacological treatment.
Int Clin Psychopharmacol. 2007;22:249-267.
(2) Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of Relapse
Following Response From a First Episode of Schizophrenia or
Schizoaffective Disorder. "Arch Gen Psychiatry. 1999; 56: 241-247.
(3) Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia
relapse with extended release quetiapine fumarate dosed once daily: A
randomized, placebo-controlled trial in clinically stable patients.
Psychiatry 2007. 2007; 4(11):34-50.
(4) American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR). Fourth Edition. Arling
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
Copyright©2007 PR Newswire.
All rights reserved
. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients2
. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis3
. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy4
. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)5
. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test6
. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.7
. CryoCor Receives FDA Approval for Right Atrial Flutter8
. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP9
. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients10
. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer11
. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma